AscellaHealth LLC, a global healthcare and specialty pharmacy solutions company, today announces its commitment to provide NeuroSolv Therapeutics LLC with AscellaHealth’s comprehensive suite of services to support NeuroSolv’s clinical development and commercialization of Perineline™, a two-part, non-surgical therapy aimed at improving the treatment options available for patients with spinal cord injury (SCI). Perineline™ allows signals to travel through the treated zone with a view to returning function to the body, through direct treatment of the Glial scar that occurs following injury to the spinal cord, combined with neural signaling interventions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711600120/en/

From left to right: Aidan Lynch, chairman, co-founder and CEO, Ros Lynch, co-founder and director and Dr. Jessica Kwok, Scientific Chair, NeuroSolv (Photo: Business Wire)

Ideation and concept development for this new therapy began under the leadership of Ros Lynch, co-founder and director of NeuroSolv, and his father Aidan Lynch, chairman, co-founder and CEO of NeuroSolv, after Ros suffered a SCI following a diving accident.

“There is a huge level of support and eagerness across the SCI community for the advancement of recovery therapies,” says Ros Lynch. “Working with scientists and physicians, our focus has been on finding the best way forward to develop a therapy that’s effective, safe and positively impacts spinal cord patients in a way no therapy has been able to do thus far.”

The grounding research of highly regarded neuro glyco scientist, Dr. Jessica Kwok, successfully demonstrated the potential for significant improvement from Perineline™ to the European Medicines Agency which granted Perineline™ an Orphan designation status in March 2022.

Aidan Lynch adds, “As we seek and secure financial investors, NeuroSolv intends to implement clinical trials and other pre-commercialization activities as a market launchpad for Perineline™. We also look forward to partnering with industry leaders in pharmaceutical manufacturing to advance our product development.”

Investors or other parties interested in supporting the development of Perineline™ are invited to contact Aidan Lynch at Aidan.lynch@neurosolvtherapeutics.com.

NeuroSolv recognizes the opportunity to raise awareness about Perineline™ and its potential impact on the effectiveness and accessibility of SCI treatment. Currently engaging with a number of leading spinal trauma hospitals and a global SCI research foundation, NeuroSolv is seeking collaboration with additional sports injury organizations and other market sector leaders, such as workers’ compensation insurers, auto insurance providers, rehabilitation hospitals and the US Department of Veterans Affairs.

SCI is defined as damage to the tight bundle of cells and nerves that sends and receives signals from the brain to and from the rest of the body. In the US, there are approximately 17,000 new cases of SCI each year, and roughly 282,000 persons are estimated to be living with SCI.

• Males represent the majority of patients with SCI related to a sports injury. The age group with the highest risk of SCI is from 16 to 30 years of age.

• Within the US, the leading cause of SCI is motor vehicle collisions, constituting 38% of new SCI each year, while 30% are due to falls, 13% are due to violence, 9% are from sports injuries and 5% are from medical and surgical etiologies.

Craig Caceci, AscellaHealth’s executive vice president and managing director, EU/UK, says, “Our organization serves as a single resource for companies like NeuroSolv, providing collaborative support throughout the entire product life cycle, from clinical trial and pre-commercialization through product launch, market access, distribution and beyond.”

Caceci points to the value of AscellaHealth’s end-to-end, comprehensive solutions for pharmaceutical manufacturers, payers and other stakeholders that are designed to improve medication access, reduce costs and enhance patient outcomes.

“We are proud to serve as a strategic resource for NeuroSolv and provide hope for the hundreds of thousands of people worldwide who are injured or diagnosed with SCI each year,” concludes Caceci.

About AscellaHealth LLC

AscellaHealth, a global Healthcare & Specialty Pharmacy solutions company, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and/or cell and gene therapies. A recipient of numerous industry awards for innovation, and a National Association of Specialty Pharmacy Strategic Channel Partner of the Year award winner, AscellaHealth’s best-in-class, patient-centric approach is built upon proprietary technology processes for novel programs and services to support the launch of specialty medications and proactively address multiple challenges, optimize clinical health outcomes, and improve quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders. Visit www.AscellaHealth.com.

About NeuroSolv Therapeutics

NeuroSolv Therapeutics is a Belfast, Northern Ireland and Baltimore, USA based ethical business which has developed and patented Perineline™, a two-part, non-surgical, therapy to treat spinal cord injury based upon Neural Signaling Interventions and direct treatment of the Glial scar. Visit www.neurosolvtherapeutics.com for more information.

Disclaimer of Endorsement: NeuroSolv and AscellaHealth neither endorse nor recommend any commercial products, processes, or services by trade name, trademark, manufacturer, or otherwise. Any references on the NeuroSolv or AscellaHealth Websites; within media materials or downloaded from this site, does not necessarily constitute or imply an endorsement or recommendation by NeuroSolv or AscellaHealth.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230711600120/en/